

BRAVECTO[®] - MORE THAN EXPECTED

Bravecto[®] Treatment has been proven to prevent tapeworm transmission¹



The insecticidal efficacy of a single treatment of either orally or topically administered fluralaner prevented *D. caninum* transmission from infected fleas to susceptible dogs for up to 12 weeks following administration¹.

NEW!

In 2020 a tapeworm claim has been registered with Act 36 and will be part of the product package insert soon!

Offer your customers the only tick, flea and mite protection that offers extended protection in a tasty chew or a convenient spot-on with BRAVECTO[®]

Bravecto[®] - Good for your patients. Good for your practice



Reference:

¹ Gopinath D, Meyer L, Smith J and Armstrong R. Topical or oral fluralaner efficacy against flea (*Ctenocephalides felis*) transmission of *Dipylidium caninum* infection to dogs. *Parasites & Vectors* volume 11, Article number: 557 (2018)

<https://parasitesandvectors.biomedcentral.com/articles/10.1186/s13071-018-3140-x>

REGISTRATION HOLDER

Intervet South Africa (Pty) Ltd | Reg.No 1991/006580/07
20 Spartan Road, Spartan, 1619, RSA | Private Bag X2026, Isando, 1600, RSA
Tel: +27 (0)11 923 9300 | Fax: +27 (0)11 392 3158 | Sales Fax: 086 603 1777 | www.msd-animal-health.co.za

Bravecto[®] Reg. No. G4083 (Act 36/1947) Contains minimum 25 mg Fluralaner per kg body weight. Bravecto[®] Spot-On Reg. No. G4292 (Act 36/1947) Each 1 ml of Bravecto[®] Spot-On contains 280 mg Fluralaner. ZA-BRV-200400171

